[go: up one dir, main page]

MX2018005715A - Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash. - Google Patents

Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash.

Info

Publication number
MX2018005715A
MX2018005715A MX2018005715A MX2018005715A MX2018005715A MX 2018005715 A MX2018005715 A MX 2018005715A MX 2018005715 A MX2018005715 A MX 2018005715A MX 2018005715 A MX2018005715 A MX 2018005715A MX 2018005715 A MX2018005715 A MX 2018005715A
Authority
MX
Mexico
Prior art keywords
nash
treatment
liver cancer
cancer associated
antagonists
Prior art date
Application number
MX2018005715A
Other languages
English (en)
Other versions
MX376312B (es
Inventor
Koizumi Shinichi
Okumura Takako
OHTANI Naoko
Kamachi Fumitaka
Mun Loo Tze
Original Assignee
Askat Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Askat Inc filed Critical Askat Inc
Publication of MX2018005715A publication Critical patent/MX2018005715A/es
Publication of MX376312B publication Critical patent/MX376312B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta invención se refiere a antagonistas del receptor 4 de prostaglandina E2 (EP4) útiles en el tratamiento de cáncer de hígado asociado con esteatohepatitis no alcohólica (NASH) en un ser humano o un animal. El método comprende la administración de uno o más de Compuesto A, Compuesto B o Compuesto C, o sales farmacéuticamente aceptables de éstos, como el(los) antagonista(5 s) de EP4. El método puede incluir una composición farmacéutica que comprende el(los) antagonista(s) de EP4 y puede incluir uno o más de otros agentes activos y/o terapias.
MX2018005715A 2016-11-04 2017-11-02 Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash MX376312B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/343,999 US10342785B2 (en) 2016-11-04 2016-11-04 Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
PCT/JP2017/039680 WO2018084230A1 (en) 2016-11-04 2017-11-02 Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer

Publications (2)

Publication Number Publication Date
MX2018005715A true MX2018005715A (es) 2018-08-09
MX376312B MX376312B (es) 2025-03-07

Family

ID=60582639

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005715A MX376312B (es) 2016-11-04 2017-11-02 Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash

Country Status (12)

Country Link
US (2) US10342785B2 (es)
EP (1) EP3344296B1 (es)
JP (1) JP6516341B2 (es)
KR (1) KR20180064438A (es)
CN (1) CN108289960B (es)
BR (1) BR112018007947A2 (es)
CA (1) CA3000237C (es)
ES (1) ES2729961T3 (es)
HK (1) HK1251162B (es)
MX (1) MX376312B (es)
RU (2) RU2717331C2 (es)
WO (1) WO2018084230A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032158A (zh) * 2017-06-30 2020-04-17 才思治疗公司 用于治疗抑郁的nk-1拮抗剂组合物和方法
AU2019255196A1 (en) * 2018-04-16 2020-11-12 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
US20210315909A1 (en) 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
JP2021530487A (ja) * 2018-07-11 2021-11-11 アリーズ セラピューティクス， インコーポレイテッド Ｅｐ４阻害剤およびその合成
CA3126484A1 (en) 2019-01-22 2020-07-30 Keythera (Suzhou) Pharmaceuticals Co. Ltd. Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
EP3722319A1 (en) * 2019-04-09 2020-10-14 Rottapharm Biotech S.r.l. Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours
CN110386941A (zh) * 2019-08-15 2019-10-29 上海邦耀生物科技有限公司 Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗
CN110680555B (zh) * 2019-11-12 2021-06-01 重庆医药高等专科学校 一种裸鼠皮下成瘤装置
IL294196A (en) * 2019-12-25 2022-08-01 Nippon Shinyaku Co Ltd Antitumor drug for use in combination with an immune checkpoint inhibitor
CN115697317A (zh) * 2020-04-08 2023-02-03 株式会社AskAt Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用
CN113577267B (zh) * 2021-09-06 2022-04-08 江西北正干细胞生物科技有限公司 Nk细胞和抗体的药物组合物及其在治疗癌症中的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE272398T1 (de) 1999-08-10 2004-08-15 Glaxo Group Ltd Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
EP1258473A4 (en) 2000-02-22 2004-09-01 Ono Pharmaceutical Co BENZOIC ACID DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL PRODUCT CONTAINING SUCH DERIVATIVES AS ACTIVE INGREDIENT
US6710205B2 (en) 2000-02-22 2004-03-23 Ono Pharmaceutical Co., Ltd. Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
WO2003086390A1 (en) 2002-04-12 2003-10-23 Pfizer Japan Inc. Imidazole compounds as anti-inflammatory and analgesic agents
RU2004133347A (ru) 2002-04-16 2005-05-10 Фудзисава Фармасьютикал Ко.,Лтд. (Jp) Лекарственное средство для профилактики и/или лечения хронического отторжения
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
MXPA06002551A (es) 2003-09-03 2006-06-20 Pfizer Compuestos de aril o heteroaril amida.
CN1946391A (zh) 2004-04-20 2007-04-11 辉瑞产品公司 包含α－2－δ配体的组合
AP2006003769A0 (en) 2004-05-04 2006-10-31 Pfizer Ortho substituted aryl or heteroaryl amide compounds
EA200601847A1 (ru) 2004-05-04 2007-04-27 Пфайзер Инк. Замещённые метиларил- или гетероариламидные соединения
CN101137656B (zh) 2005-03-11 2010-12-22 拉夸里亚创药株式会社 咪唑衍生物的晶型
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
JP5289046B2 (ja) 2005-05-19 2013-09-11 メルク カナダ インコーポレイテッド Ｅｐ４アンタゴニストとしてのキノリン誘導体
HRP20151102T1 (xx) 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
JP6087503B2 (ja) 2008-09-26 2017-03-08 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ヒト抗ｐｄ−１、ｐｄ−ｌ１、及びｐｄ−ｌ２抗体とその用途
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
SMT202500126T1 (it) 2008-12-09 2025-05-12 Hoffmann La Roche Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t
JP5668219B2 (ja) * 2009-04-22 2015-02-12 ラクオリア創薬株式会社 癌治療のための選択的ｅｐ４受容体拮抗物質
EP2482849B1 (en) 2009-09-30 2018-06-06 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
KR101780666B1 (ko) * 2010-02-22 2017-09-21 에스크엣 인크. Ｉｌ-23 매개 질환의 치료에서 ｅｐ4 수용체 길항제의 용도
AU2012308491B2 (en) 2011-09-16 2016-01-07 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
CN106102774A (zh) * 2013-12-17 2016-11-09 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
KR102535283B1 (ko) 2014-05-23 2023-05-22 에자이 알앤드디 매니지먼트 가부시키가이샤 암의 치료를 위한 조합 요법

Also Published As

Publication number Publication date
MX376312B (es) 2025-03-07
RU2020109376A (ru) 2020-04-29
CN108289960B (zh) 2021-07-09
RU2717331C2 (ru) 2020-03-23
JP2018535939A (ja) 2018-12-06
JP6516341B2 (ja) 2019-05-22
BR112018007947A2 (pt) 2018-10-30
US10583129B2 (en) 2020-03-10
US10342785B2 (en) 2019-07-09
RU2018117891A3 (es) 2019-11-18
KR20180064438A (ko) 2018-06-14
HK1253277A1 (zh) 2019-06-14
HK1251162B (en) 2020-01-17
CA3000237A1 (en) 2018-05-04
WO2018084230A1 (en) 2018-05-11
ES2729961T3 (es) 2019-11-07
EP3344296B1 (en) 2019-05-15
US20190269663A1 (en) 2019-09-05
RU2762193C2 (ru) 2021-12-16
CA3000237C (en) 2019-02-26
US20180125832A1 (en) 2018-05-10
RU2018117891A (ru) 2019-11-18
CN108289960A (zh) 2018-07-17
EP3344296A1 (en) 2018-07-11
RU2020109376A3 (es) 2020-10-27

Similar Documents

Publication Publication Date Title
MX2018005715A (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash.
CL2019002470A1 (es) Combinaciones de un derivado de 4-pirimidinsulfamida con ingredientes activos para el tratamiento de enfermedades relacionadas con endotelina.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX2020011868A (es) Inhibidores de los receptores erbb.
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
BR112017007662A8 (pt) Composto, composição farmacêutica e uso de um composto
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
CL2019000245A1 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
EA201892119A1 (ru) Лекарственный препарат, полученный путем комбинирования агониста fxr и arb
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
MX2018004664A (es) Antagonistas de ep4.
CR20160527A (es) Derivados de carboxamida
CL2019003533A1 (es) Uso de vibegron para tratar vejiga sobreactiva.
CY1124301T1 (el) Ενωσεις ινδαζολης για χρηση σε κακωσεις του τενοντα ή/και των συνδεσμων
DOP2019000299A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
MX389729B (es) Uso de antagonistas de aplnr e inhibidores de vegf para tratar trastornos oculares.
AR108792A1 (es) Composiciones que comprenden timolol
CR20190401A (es) Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas
MX2017014471A (es) Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia.

Legal Events

Date Code Title Description
FG Grant or registration